U0126 attenuates p-Cdk5^S159 increase and Cdk5 activity in SCDH induced by CFA administration.

Abstract

<p>a. U0126 mitigates CFA-induced p-ERK1/2 and p-Cdk5 increases in spinal cord in the Western blot analysis. b and c. Quantification of the Western blot shows that ERK1/2 activity by CFA is attenuated after U0126 treatment, *p<0.05, **p<0.01. d. Quantification of the Western blot shows that the increase of p-Cdk5^S159 by CFA is attenuated after U0126 treatment, **p<0.01, ***p<0.001. e. U0126 treatment does not affect total-ERK1/2 and total-Cdk5 expression in spinal cord 1 d after CFA injection. f. U0126 mitigates CFA-induced Cdk5 kinase activity in spinal cord detected by an in vitro phosphorylation assay. Histone H1 was used as a substrate. g. Quantification of Cdk5 activity (density of phosphorylated H1 band) in the SCDH. Columns represent means ± SEM for three separate experiments. h. Double-immunofluorescence staining for p-ERK (red), p-Cdk5 (green), Hoechst [a cell nuclear marker (blue)] in ipsilateral spinal enlargement at 1 day after CFA injection. P-Cdk5^S159 colocalizes with p-ERK (white arrow head).</p